Quick Answer
TEVA PHARMACEUTICAL INDUSTRIES LTD reported Net Income Loss of $1.41 billion for the year ending 2025.
- TEVA PHARMACEUTICAL INDUSTRIES LTD showed an increase of +186.0% in Net Income Loss from 2024 to 2025.
- This data is from TEVA PHARMACEUTICAL INDUSTRIES LTD's annual report (Form 10-K), filed with the SEC on February 3, 2026.
- XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: $645.00 million | Q2 2017: -$5.97 billion | Q3 2017: $595.00 million | Q4 2017: -$11.54 billion | Q1 2018: $1.12 billion | Q2 2018: -$176.00 million | Q3 2018: -$208.00 million | Q4 2018: -$2.89 billion | Q1 2019: -$105.00 million | Q2 2019: -$689.00 million | Q3 2019: -$314.00 million | Q4 2019: $110.00 million | Q1 2020: $69.00 million | Q2 2020: $140.00 million | Q3 2020: -$4.35 billion | Q4 2020: $150.00 million | Q1 2021: $77.00 million | Q2 2021: $207.00 million | Q3 2021: $292.00 million | Q1 2022: -$955.00 million | Q2 2022: -$251.00 million | Q3 2022: $61.00 million | Q4 2022: -$1.30 billion | Q1 2023: -$220.00 million | Q2 2023: -$872.00 million | Q3 2023: $69.00 million | Q1 2024: -$139.00 million | Q2 2024: -$846.00 million | Q3 2024: -$437.00 million | Q1 2025: $214.00 million | Q2 2025: $282.00 million | Q3 2025: $433.00 million.
- Over the full 18 years of available data (2008 to 2025), TEVA PHARMACEUTICAL INDUSTRIES LTD's Net Income Loss has grown by 131.5%.
- Historical annual values: Fiscal year 2025: $1.41 billion | Fiscal year 2024: -$1.64 billion | Fiscal year 2023: -$559.00 million | Fiscal year 2022: -$2.45 billion | Fiscal year 2021: $417.00 million | Fiscal year 2020: -$3.99 billion | Fiscal year 2019: -$999.00 million | Fiscal year 2018: -$2.15 billion | Fiscal year 2017: -$16.27 billion | Fiscal year 2016: $329.00 million | Fiscal year 2015: $1.59 billion | Fiscal year 2014: $3.06 billion | Fiscal year 2013: $1.27 billion | Fiscal year 2012: $1.96 billion | Fiscal year 2011: $2.76 billion | Fiscal year 2010: $3.33 billion | Fiscal year 2009: $2.00 billion | Fiscal year 2008: $609.00 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: